Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/30/15 → 8/30/17 |
Funding
- Nivalis Therapeutics Incorporated: $44,539.00
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with lumacaftor/ivacaftor (ORKAMBI)
- Anstead, Michael (PI)
- Danov, Zoran (CoI)
- Kanga, Jamshed (CoI)
- Tupayachi Ortiz, Maria (CoI)